

## PRESS RELEASE

**Q2 2008 SALES UP 18%**  
**1ST HALF-YEAR SALES UP 16%**  
**REVISION UPWARDS OF 2008 SALES GROWTH GUIDANCE: ≥12%**

**Antony, France; 10 July 2008 – 6pm.**

€ millions	2006		2007		07/06 % change	2008		08/07 % change
	€M	%Sales	€M	%Sales		€M	%Sales	
Southern Europe (1)	20,5	72	23,2	72	13	26,8	71	15
Other EU countries (2)	6,9	24	7,7	24	11	9,3	24	20
Other markets	1,2	4	1,3	4	15	2,0	5	47
SLIT	21,8	76	25,1	77	15	30,4	80	21
SCIT	5,4	19	5,6	18	5	6,1	16	7
Other products	1,5	5	1,5	5	(0)	1,6	4	4
<b>Total Q2 sales</b>	<b>28,6</b>	<b>100</b>	<b>32,2</b>	<b>100</b>	<b>13</b>	<b>38,0</b>	<b>100</b>	<b>18</b>
Southern Europe (1)	48,1	75	56,5	76	18	64,7	75	14
Other EU countries (2)	13,7	21	15,8	21	15	18,6	21	18
Other markets	2,4	4	2,5	3	5	3,7	4	46
SLIT	49,4	77	59,7	80	21	71,3	82	19
SCIT	11,6	18	11,8	16	2	12,3	14	4
Other products	3,2	5	3,2	4	3	3,4	4	6
<b>Total H1 sales</b>	<b>64,2</b>	<b>100</b>	<b>74,8</b>	<b>100</b>	<b>17</b>	<b>87,0</b>	<b>100</b>	<b>16</b>

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

2008 second quarter sales recorded strong growth in all markets (+18% vs +13% in 2007). Eastern European markets and other markets outside Europe made a significant contribution to this growth. The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared to the first half 2007, when growth was already particularly strong (+ 17%). This good performance has enabled the Group to revise its sales growth guidance upwards to growth of at least 12% in 2008 (vs ≥10% previously), boosted by the growing success of the sublingual route, in which Stallergenes continues to strengthen its leadership.

The commercial launch of ORALAIR® Grasses for adults will take place in Germany in the next few weeks, following the grant, on 24 June 2008, of the marketing authorisation. The request for a paediatric extension of ORALAIR® Grasses has been filed with the Paul Ehrlich Institute. The application for clinical studies for ORALAIR® Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a strong level of activity and will show a marked improvement compared to 2007. These results will be released on 27 August 2008.

## ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatment, Stallergenes devotes 16% of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and is part of the sample composing the SBF 120 index.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP



Additional information is available on <http://www.stallergenes.com>

### Contacts

Albert Saporta – Chairman

Tel.: +33 1 55 59 20 04

Christian Thiry- Chief Financial Officer

Tel.: +33 1 55 59 20 95 – e-mail : [investorrelations@stallergenes.fr](mailto:investorrelations@stallergenes.fr)

### Press Relations Stallergenes

Lise Lemonnier – Communications Manager

Tel.: + 33 1 55 59 20 96 – e-mail : [llemonnier@stallergenes.fr](mailto:llemonnier@stallergenes.fr)

### Investors and analysts relations

#### Pavie Finance

Lucile de Fraguier – Tel.: + 33 1 42 15 04 39 – E-mail: [contact@pavie-finance.com](mailto:contact@pavie-finance.com)